Using standard platinum-based chemotherapy is often associated with the formation of unfavorable treatment-resistant cancer stem cells, which may ultimately contribute to cancer progression — but inhibiting an enzyme called NAMPT may be able to prevent this detrimental effect, a study in mice found.  In animal models of ovarian cancer, adding a NAMPT inhibitor to cisplatin treatment not only blocked the outgrowth of chemoresistant stem-like cancer cells. It also delayed tumor relapse and significantly extended survival. These findings have implications for ovarian cancer patients successfully treated with platinum-based therapies who are at risk for cancer relapse.  The study, “NAMPT inhibition suppresses cancer stem-like cells associated with therapy-induced senescence in ovarian cancer,” was published in the journal Cancer Research.  Platinum-based chemotherapies, such as cisplatin, are the standard-of-care treatment for epithelial ovarian cancer. They wo

Subscribe or log in to access all post and page content.